UroGen Pharma Ltd. (URGN)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 12.91 |
| Open | 12.87 |
| Bid | 13.23 x 100 |
| Ask | 13.31 x 100 |
| Day's range | 12.87 - 13.58 |
| 52-week range | 8.69 - 24.13 |
| Volume | |
| Avg. volume | 328,925 |
| Market cap | 479.446M |
| Beta (5Y monthly) | 1.09 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.31 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 38.00 |
Simply Wall St.UroGen Pharma First Quarter 2024 Earnings: Misses Expectations
UroGen Pharma ( NASDAQ:URGN ) First Quarter 2024 Results Key Financial Results Revenue: US$18.8m (up 9.2% from 1Q...
GuruFocus.comUroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations
Insight into UroGen Pharma's First Quarter Financial Performance and Strategic Highlights
Business WireUroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights
PRINCETON, N.J., May 13, 2024--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2024, and provided an overview of recent developments.
© 2024 Yahoo. All rights reserved.